Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Public ClinicalTrials.gov record NCT03221257. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Study identification
- NCT ID
- NCT03221257
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Michael Roth
- Other
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Interventions
- Mycophenolate Mofetil (MMF) Drug
- Pirfenidone (PFD) Drug
- Placebo (Plac) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2017
- Primary completion
- Mar 22, 2022
- Completion
- Jun 12, 2022
- Last update posted
- Dec 14, 2023
2017 – 2022
United States locations
- U.S. sites
- 16
- U.S. states
- 15
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Indiana University Health | Indianapolis | Indiana | 46202 | — |
| Johns Hopkins University | Baltimore | Maryland | 21224 | — |
| Harvard Medical School, Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| Boston University, School of Medicine | Boston | Massachusetts | 02118 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Rutgers University | New Brunswick | New Jersey | 08901 | — |
| Hospital for Special Surgery | New York | New York | 10021 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15261 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| University of Texas Medical School at Houston | Houston | Texas | 77030 | — |
| University of Utah | Salt Lake City | Utah | 84108 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03221257, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2023 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03221257 live on ClinicalTrials.gov.